<DOC>
	<DOCNO>NCT01937923</DOCNO>
	<brief_summary>This observational study establish clinical baseline measure change time movement , think , behavior , brain imaging , blood spinal fluid marker subject early stage Huntington 's disease . Participants enrol study may eligible participate future plan study stem cell therapy Huntington 's Disease ( HD ) . In-person study visit occur screen , baseline , every 6 month thereafter minimum 12 month , interim phone call assessment .</brief_summary>
	<brief_title>A Pre-Cellular Therapy Observational Study Early Huntington 's Disease</brief_title>
	<detailed_description>In PRE-CELL investigator propose enroll cohort early-stage HD patient prospective observational study design characterize clinical , neuro-imaging , laboratory biomarker correlate disease progression 12-18 month . Subjects complete minimum 12 month ' participation trial candidate enrollment future plan Phase 1 trial intrastriatal delivery mesenchymal stem cell ( MSC ) /Brain-derived neurotrophic factor ( BDNF ) .</detailed_description>
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Men woman age 18 old , English speaking , able give inform consent comply study procedure . HD diagnosis confirm genetic testing demonstrate CAG trinucleotide repeat length ( CAGn ) great 37 Early stage HD Total Functional Capacity ( TFC ) score 913 Demonstrable motor sign Unified Huntington 's Disease Rating Scale ( UHDRS ) diagnostic confidence level 4 Must caregiver informant able give feedback participant willing report observation subject standardize form . Subjects child bear potential must agree adequate birth control measure include intrauterine device , hormone therapy , hormone ring barrier method include foams/gels AND condom . Very early disease without demonstrable motor sign ( diagnostic confidence level &lt; 4 ) Significant cognitive impairment dementia define Montreal Cognitive Assessment ( MoCA ) score &lt; 12 . Moderate advance disease TFC &lt; 9 Concurrent active unstable psychiatric disease include history suicide attempt within last year , major personality psychiatric disorder . History concurrent serious medical illness HIV current antiretroviral treatment , cancer , major cardiac , pulmonary , immunological organ disease . History coagulopathy , bleed disorder , concurrent use blood thinner . History brain tumor , serious traumatic brain injury coma , history brain surgery . Any comorbid condition present unacceptable health risk patient investigator 's view Clinically significant laboratory test abnormality , include full blood count , chemistry panel , liver function test , Prothrombin time/international normalize ratio ( PT/INR ) , lipid panel , electrocardiogram ( EKG ) , chest xray judge investigator . Active drug alcohol use dependence , opinion site investigator , would interfere safety adherence study requirement . History documentation contraindication MRI brain scan , include presence pacemaker , neurostimulator , aneurysm clip , artificial heart valve , cochlear implant , metal fragment eye , orbit skin know contraindication MRI . Any significant MRI brain scan finding characteristic HD . Any contraindication surgery use general anesthesia , include allergy . History use investigational agent within 60 day prior enrollment History current previous gene therapy stem cell therapy . History previous current treatment cytokine History sensitivity ganciclovir . Pregnant and/or lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>